



Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



Ref.: ISLL:CH:2022:

Date: 08th February, 2022

The President,
Corporate Relationship Department,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

The Vice President,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor,
Plot No.C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

BSE Scrip Code: 532305

NSE Symbol: INDSWFTLAB

Sub: Intimation of Investment in a Joint Venture

Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of the Company has approved an Investment in a Joint Venture on a 50:50 basis.

The disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is enclosed as Annexure I to this intimation.

We request you to take the same on record.

Thanking you,
For IND-SWIFT LABORATORIES LTD.

PARDEEP VERMA
AVP-CORPORATE AFFAIRS &
COMPANY SECRETARY



Encl: As Above



Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
 CIN No. L24232CH1995PLC015553



Annexure-I

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

Sr. No.	Particulars	
1.	Name of the Target entity	INDIS HEALTHCARE LLP
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	The investment will not fall into a related party transaction. Ind-Swift Laboratories Limited (ISLL) will be holding 50% Stake in the Joint Venture entity.
3.	Industry to which Target entity being acquired belongs	The Target Entity belongs to Healthcare industry.
4.	Objects and effects of acquisition	To explore business opportunities available in the Pharma space other than the pharma segment in which ISLL is already present .
5.	Brief details of any governmental or regulatory approvals required for the acquisition.	Normal Regulatory Approvals as are required to run a pharma Business shall be obtained in due course .
6	Indicative time period for completion	The Investment will be an on-going investment to be undertaken from time to time as per the need of the Joint Venture.
7	Nature of consideration - Whether Cash consideration or share swap and details of the same	Cash consideration
8	Percentage of shareholding/ control acquired and/ or number of shares acquired	ISLL shall hold 50% stake in the LLP.
9	Cost of acquisition or the price at which the shares are acquired	Initially the Board has approved an investment of upto Rs. 10 crores , which will be invested over a period of time.
10	Brief Background about entity acquired in terms of Products/line of business acquired, Date of incorporation, History of last 3 years Consolidated turnover (Rs. in lakhs), Country in which the acquired entity has presence and any	ISLL has entered into joint Venture with M/s Wellgen Medicare Private Limited and Mr. Anshul Jain, who shall hold 30% & 20% stake respectively and 50% stake shall be held by ISLL in the joint Venture.





Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



	other significant information (in brief)	The Joint Venture will be run through a newly incorporated Limited Liability Partnership (LLP), incorporated on 14.01.2022, with focus to have presence in the Pharma segments in which ISLL is not having any presence as on date .
--	--	--

